MedTrace Logo

Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts

NCT02506998 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-07-28

No results posted yet for this study

Summary

The purpose of this study is to determine the changes of quality of life of patients with allergic rhinoconjunctivitis treated with standard medications plus Dialyzable Leukocyte Extracts (DLE). All patients will receive DLE in combination with current guide lines-suggested standard medication.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

DLE

Adjuvant treatment

OTHER

Second generation anti histamines + Nasal corticosteroids

Standard treatment

Sponsors & Collaborators

  • Instituto de Oftalmología Fundación Conde de Valenciana

    collaborator OTHER

  • National Polytechnic Institute, Mexico

    lead OTHER

Principal Investigators

  • Toni Homberg, MD · National Polytechnic Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02506998 on ClinicalTrials.gov